Dual-tracer PET/CT protocol with [18F]FDG and [68Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [18F]FDG in different cancer types, resulting in larger functional and gross tumor volume

[1] Santi A(2018)Cancer associated Fibroblasts: the architects of stroma remodeling Proteomics 18 e1700167-7239

[2] Kugeratski FG(1990)Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers Proc Natl Acad Sci U S A 87 7235-805

[3] Zanivan S(2019)(68)ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer J Nucl Med 60 801-3335

[4] Garin-Chesa P(1993)Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin Cancer Res 53 3327-1422

[5] Old LJ(2020)Clinical results of fibroblast activation protein (FAP) specific PET and implications for radiotherapy planning: systematic review Cancers 59 1415-1177

[6] Rettig WJ(2018)Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein J Nucl Med 61 1171-1931

[7] Kratochwil C(2020)Radiation dosimetry and biodistribution of (68)ga-FAPI-46 PET imaging in cancer patients J Nucl Med 48 1915-163

[8] Flechsig P(2021)Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET/CT in patients with various cancers Eur J Nucl Med Mol Imaging 150 159-203

[9] Lindner T(2021)Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients Eur J Nucl Med Mol Imaging 48 196-1500

[10] Abderrahim L(2020)Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma Radiother Oncol 22 1495-23

[1] Santi A(2018)Cancer associated Fibroblasts: the architects of stroma remodeling Proteomics 18 e1700167-7239

[2] Kugeratski FG(1990)Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers Proc Natl Acad Sci U S A 87 7235-805

[3] Zanivan S(2019)(68)ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer J Nucl Med 60 801-3335

[4] Garin-Chesa P(1993)Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin Cancer Res 53 3327-1422

[5] Old LJ(2020)Clinical results of fibroblast activation protein (FAP) specific PET and implications for radiotherapy planning: systematic review Cancers 59 1415-1177

[6] Rettig WJ(2018)Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein J Nucl Med 61 1171-1931

[7] Kratochwil C(2020)Radiation dosimetry and biodistribution of (68)ga-FAPI-46 PET imaging in cancer patients J Nucl Med 48 1915-163

[8] Flechsig P(2021)Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET/CT in patients with various cancers Eur J Nucl Med Mol Imaging 150 159-203

[9] Lindner T(2021)Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients Eur J Nucl Med Mol Imaging 48 196-1500

[10] Abderrahim L(2020)Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma Radiother Oncol 22 1495-23